Table 2 Clinicopathologic characteristics of high- and low-volumetric SMI groups
Characteristics | High-volumetric SMI (n = 193, %) | Low-volumetric SMI (n = 192, %) | P |
|---|---|---|---|
Age, years | |||
Mean ± SD | 53.1 ± 10.7 | 58.0 ± 10.6 | < 0.001 |
BMI, kg/m2 | |||
Median (IQR) | 26.0 (23.7–29.1) | 22.9 (21.0–25.0) | < 0.001 |
Underweight (< 18.5) | 1 (0.5) | 8 (4.2) | < 0.001 |
Normal (18.5–22.9) | 36 (18.7) | 87 (45.3) | |
Overweight (23.0–24.9) | 47 (24.4) | 40 (20.8) | |
Obesity (≥ 25.0) | 109 (56.5) | 57 (29.7) | |
Comorbidities | |||
Hypertension | 56 (29.0) | 51 (26.6) | 0.591 |
Diabetes | 26 (31.5) | 20 (10.4) | 0.355 |
Dyslipidemia | 41 (21.2) | 36 (18.8) | 0.541 |
Histologic type | 0.139 | ||
Endometrioid | 168 (87.0) | 147 (76.6) | |
Mucinous | 0 | 1 (0.5) | |
Serous | 10 (5.2) | 15 (7.8) | |
Clear cell | 2 (1.0) | 6 (3.1) | |
Mixed | 3 (1.6) | 4 (2.1) | |
Carcinosarcoma | 10 (5.2) | 19 (9.9) | |
Grade | 0.005 | ||
1 | 103 (53.4) | 82 (42.7) | |
2 | 51 (26.4) | 43 (22.4) | |
3 | 39 (20.2) | 67 (34.9) | |
2009 FIGO stage | 0.305 | ||
Four categories | |||
I | 145 (75.1) | 133 (69.3) | |
II | 6 (3.1) | 11 (5.7) | |
III | 34 (17.6) | 34 (17.7) | |
IV | 8 (4.1) | 14 (7.3) | |
Two categories | 0.453 | ||
I–II | 151 (78.2) | 144 (75.0) | |
III–IV | 42 (21.8) | 48 (25.0) | |
CA-125, IU/ml | |||
Median (IQR) | 18.3 (11.9–34.3) | 17.3 (9.5–31.2) | 0.158 |
Pathologic risk factors | |||
Myometrial invasion, ≥ 50% | 49 (25.4) | 62 (32.3) | 0.135 |
LVSI | 52 (26.9) | 60 (31.3) | 0.352 |
Pelvic LN metastasis* | 26 (13.5) | 26 (13.5) | 0.934 |
Para-aortic LN metastasis† | 13 (6.7) | 11 (5.7) | 0.657 |
Adjuvant treatment | 0.681 | ||
No | 118 (61.1) | 111 (57.8) | |
Radiation only | 22 (11.4) | 23 (12.0) | |
Chemotherapy only | 25 (13.0) | 33 (17.2) | |
CCRT | 28 (14.5) | 25 (13.0) | |